陳志豪

JH Chern 2陳志豪  副研究員
生技與藥物研究所
Email: jhchen@nhri.edu.tw

 

EDUCATION

  • Ph.D., Organic Chemistry, National Chiao Tung University (1997)
  • B.S., Chemistry, Tamkang University ( 1989)

PROFESSIONAL EXPERIENCES

  • Associate Investigator, Institute of Biotechnology and Pharmaceutical Research, NHRI ( 2006 – present)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, NHRI (2002 – 2006)
  • Research Associate, Division of Biotechnology and Pharmaceutical Research, NHRI (2000 – 2002)
  • Postdoctoral Fellow, Division of Biotechnology and Pharmaceutical Research, NHRI (1998 – 2000)
  • Postdoctoral Fellow, Institute of Chemistry, Academia Sinica (1997- 1998)

RESEARCH INTERESTS

Dr. Chern’s research interests are deeply involved in four major areas: (1) Discovery of a novel class of potent, selective, and orally bioavailable EV71 capsid binders and identification of clinical candidate DBPR103 for the treatment of enterovirus 71 infection; (2) Discovery of a novel class of potent, selective, and orally bioavailable HCV NS5A inhibitors and identification of clinical candidate DBPR110 for the treatment of hepatitis C virus infection; (3) Discovery of potent inhibitors targeting on glutaminyl cyclase (sQC) as new drugs for the treatment of Alzheimer’s disease (AD); (4) Discovery and development of potent isoQC inhibitors targeting the CD47-SIRP axis as novel immunotherapeutic agents for the treatment of cancer.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Chern was trained as a synthetic chemist during the period of Ph.D. and postdoctoral studies. Dr. Chern has a professional career with more than 15 years of pharmaceutical experiences in antiviral research. Dr. Chern published a number of decent research articles, e.g. Journal of Organic Chemistry, Tetrahedron, Tetrahedron Letters, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, and Bioorganic & Medicinal Chemistry Letters. Some of papers are highly cited. Since 2002, Dr. Chern focused on drug discovery and development of anti-enterovirus (EV) and anti-hepatitis C virus (HCV) agents. Several potential antiviral compounds have been discovered and published in the prestigious medicinal chemistry journals. In particular, a novel, potent, and orally bioavailable HCV NS5A inhibitor, DBPR110, has been successfully developed as an anti-HCV drug candidate for clinical development. Technology transfer agreement of DBPR110 was signed and transferred to Microbio Co. Ltd. for further clinical development on April 11th, 2013. DBPR110 discovery team (Drs. Jyh-Haur Chern, Andrew Yueh, Teng-Kuang Yeh) was awarded “Outstanding Technology Transfer Award” medal by Ministry of Science and Technology in 2013. Dr. Chern was in charge of the preparation of the Chemistry Manufacturing and Controls (CMC) of DBPR110 (also known as MB110) for investigational new drug (IND) application of USFDA. As expected, USFDA accepted the IND application of MB110 for the treatment of patients infected with HCV on Dec. 17th, 2015. In collaboration with Dr. Andrew H.-J. Wang in Academia Sinica, Dr. Chern focus on the discovery of potent Inhibitors targeting on glutaminyl cyclase (QC) as new drugs for treatment of Alzheimer’s disease in the past 5 years. Recently, BPRQC298 was identified as a novel, potent, and orally bioavailable QC inhibitor with excellent pharmacology profiles. It presented a promising lead candidate for further development.

HONORS & AWARDS

  • 2016年 榮獲台北生技獎「技轉合作獎」銀獎
  • 2014年 榮獲經濟部智慧財產局「103年國家發明創作獎」發明獎金牌
  • 2013年 榮獲國科會「102年度傑出技術移轉貢獻獎」

TECHNOLOGY TRANSFER

2013年 財團法人國家衛生研究院與中天生技簽訂 「小分子C型肝炎病毒抑制劑 DBPR110 及其衍生物」之全球專屬技術授權合約。

PUBLICATIONS

  1. Jheng, J.R.; Hsieh, C.F.; Chang, Y.H.; Ho, J.Y.; Tang, W.F.; Chen, Z.Y.; Liu, C.J.; Lin, T.J.; Huang, L.Y.; Chern, J.H.; Horng, J.T. “Rosmarinic acid interferes with influenza virus A entry and replication by decreasing GSK3beta and phosphorylated AKT expression levels” J. Microbiol. Immunol. Infect. 2022 (in press). (IF=10.273; 15/94 (16%) /Infectious Diseases)
  2. Hsieh, C.F.; Jheng, J.R.;Lin, G.H.; Chen, Y.L.; Ho, J.Y.; Liu, C.J.; Hsu, K.Y.; Chen, Y.S.; Chan, Y.F.; Yu, H.M.; Hsieh, P.W.; Chern, J.H.*; Horng, J.T.* “Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors” Emerg. Microbes Infect. 2020, 9 (1), 1194-1205. (IF=7.163; 6/93 (6%) /Infectious Diseases)
  3. Yang, C.C.; Hu, H.S.; Lin, H.M.; Wu, R.H.; Wu, P.S.; Wu, S.H.; Tsou, L.K.; Song, J.S.; Chern, J.H.; Chen, C.T.; Yueh, A. “A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses” Antiviral Research 2019, 172, 104636. (IF=4.130; 50/267 (19%) /Pharmacology & Pharmacy)
  4. Yeh, T.K.; Kang I.J.; Hsu T.A.; Lee, Y.C.; Lee, C.C.; Hsu, S.J.; Tian, Y.W.; Yang, H.Y.; Chen, C.T.; Chao, Y.S.; Yueh A.*; Chern, J.H.* “A Novel, Potent, and Orally Bioavailable Thiazole HCV NS5A Inhibitor for the Treatment of Hepatitis C Virus” Eur. J. Med. Chem. 2019, 167, 245-268. (*corresponding author) (IF=4.666; 5/61 (8%) /Chemistry, Medicinal)
  5. Lin, H.M.; Wu, P.S.; Hu, H.S.; Chang, W.C.; Wu, R.H.; Tian, J.N.; Chern, J.H.; Yueh, A. “Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication” J. Virol. Methods 2018, 259, 10-17. (IF=1.656; 62/79 (78%) /Biochemical Research Methods)
  6. Wu, S.N.; Chern, J.H.; Shen, S.; Chen, H.H.; Hsu, Y.T.; Lee, C.C.; Chan, M.H.; Lai, M.C.; Shie, F.S. “Stimulatory actions of a novel thiourea derivative on large-conductance, calcium-activated potassium channels” J. Cell. Physiol. 2017, 232(12), 3409-3421. (IF=4.085; 13/83 (15%) /Physiology)
  7. Kang, I.J.; Hsu, S.J.; Yang, H.Y.; Yeh, T.K.; Lee, C.C.; Lee, Y.C.; Tian, Y.W.; Song, J.S.; Hsu, T.A.; Chao, Y.S.; Yueh A.*; Chern, J.H.* “A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1- ((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl) pyrrolidine carboxamide” J. Med. Chem. 2017, 60(1), 228-247. (*corresponding author) (IF=6.060; 3/59 (5%) /Chemistry, Medicinal)
  8. Wu, R.H.; Tsai, M.H.; Tsai, K.N.; Tian, C.N.; Chen, C.S.; Wu, S.Y.; Chern, J.H.; Chen, C.H.; Yueh, A. “Mutagenesis of Dengue Virus Protein NS2A Revealed a Novel Domain Responsible for Virus-Induced Cytopathic Effect and Interactions Between NS2A and NS2B Transmembrane Segments” J. Virol. 2017, 91(12), e01836-16. (IF=4.259; 8/35 (23%) /Virology)
  9. Ho, J.Y.#; Chern, J.H.#; Hsieh, C.F.; Liu, S.T.; Liu, C.J.; Wang, Y.S.; Kuo, D.W.; Hsu, S.J.; Yeh, T.K.; Shih, S.R.; Hsieh, P.W.; Chiu, C.H.; Horng, J.T. “In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71” J. Antimicrob. Chemother. 2016, 71(7), 1922-1932. (#equal contribution) (IF=4.919; 9/83 (11%) /Infectious Disease)
  10. Yang, C.C.; Hu, H.S.; Wu, R.H.; Wu, S.H.; Lee, S.J.; Jiaang, W.T.; Chern, J.H.; Huang, Z.S.; Wu, H.N.; Chang, C.M.; Yueh, A. “A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease” Antimicrob. Agents Chemother. 2014, 58(1), 110-119. (IF=4.415; 22/123 (18%) /Microbiology)
  11. Lin, H.M.; Wang, J.C.; Hu, H.S.; Wu, P.S.; Wang, W.H.; Wu, S.Y.; Yang, C.C.; Yeh, T.K.; Hsu, T.A.; Jiaang, W.T.; Chao, Y.S.; Chern, J.H.*; Yueh, A.* “Resistance studies of a di-thiazol analogue, DBPR110, as a potential Hepatitis C virus NS5A inhibitor in replicon systems. “ Antimicrob. Agents Chemother. 2013, 57(2), 723-733. (*co-corresponding author) (IF=4.415; 22/123 (18%) /Microbiology)
  12. Lin, H.M.; Wang, J.C.; Hu, H.S.; Wu, P.S.; Yang, C.C.; Wu, C.P.; Pu, S.Y.; Hsu, T.A.; Jiaang, W.T.; Chao, Y.S.; Chern, J.H.; Yeh, T.K.; Yueh, A. “Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.” Antimicrob. Agents Chemother. 2012, 56(1), 44-53. (IF=4.415; 22/123 (18%) /Microbiology)
  13. Yang, C.C.; Hsieh, Y.C.; Lee, S.J.; Wu, S.H.; Liao, C.L.; Tsao, C.H.; Chao, Y.S.; Chern, J.H.; Wu, C.P.; Yueh, A. “Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay” Antimicrob. Agents Chemother. 2011, 55(1), 229-238. (IF=4.415; 22/123 (18%) /Microbiology)
  14. Kang, I.J.; Wang, L.W.; Hsu, T.A.; Yueh, A.; Lee, C.C.; Lee, Y.C.; Lee, C.Y.; Chao, Y.S.; Shih, S.R.; Chern, J.H.* “Isatin-beta-thiosemicarbazones as potent herpes simplex virus inhibitors” Bioorg. Med. Chem. Lett. 2011, 21(7), 1948-1952. (*corresponding author) (IF=2.486; 23/59 (39%) /Chemistry, Organic)
  15. Hu, C.B.; Chen, C.P.; Yeh, T.K.; Song, J.S.; Chang, C.Y.; Chuu, J.J.; Tung, F.F.; Ho, P.Y.; Chen, T.W.; Lin, C.H.; Wang, M.H.; Chang, K.Y.; Huang, C.L.; Lin, H.L.; Li, W.T.; Hwang, D.R.; Chern, J.H.; Hwang, L.L.; Chang, J.Y.; Chao, Y.S.; Chen, C.T. “BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities” Cancer Science 2011, 102(1), 182-191. (IF=3.896; 62/213 (29%) /Oncology)
  16. Li, S.L.; Huang, C.H.; Lin, C.C.; Huang, Z.N.; Chern, J.H.; Lien, H.Y.; Wu, Y.Y.; Cheng, C.H.; Chang, C.Y.; Chuu, J.J. “Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer” Investigational New Drugs. 2011, 29 (2), 195-206. (IF=3.281; 65/255 (25%) /Pharmacology & Pharmacy)
  17. Kang, I.J.; Wang, L.W.; Hsu, S.J.; Lee, C.C.; Lee, Y.C.; Wu, Y.S.; Yueh, A.; Wang, J.C.; Hsu, T.A.; Chao, Y.S.; Chern, J.H.* “Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogues as novel hepatitis C virus inhibitors” Bioorg. Med. Chem., 2010, 18 (17), 6414-6421. (*corresponding author) (IF=2.923; 20/59 (34%) /Chemistry, Medicinal)
  18. Chern, J.H.; Hsu, P.C.; Kang, I.J.; Wang, L.W.; Tsay, H.J.; Shie, F.S. “Modulation of microglial immune responses by a novel thiourea derivative” Chem. Biol. Interact. 2010, 188 (1), 228-236. (IF=2.618; 98/255 (38%) /Pharmacology & Pharmacy)
  19. Chen, T.C.; Chang, H.Y.; Lin, P.F.; Chern, J.H.; Hsu, J.T.; Chang, C.Y.; Shih, S.R. “Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71” Antimicrob. Agents Chemother. 2009, 53 (7), 2740-2747. (IF=4.415; 22/123 (18%) /Microbiology)
  20. Kang, I.J.; Wang, L.W; Hsu, S.J; Lee, C.C.; Lee, Y.C.; Wu, Y.S.; Yueh, A.; Wang, J.C.; Hsu, T.A.; Chao, Y.S.; Chern, J.H.* “Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors” Bioorg. Med. Chem. Lett., 2009, 19, 6063-6068. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  21. Kang, I.J.; Wang, L.W.; Hsu, S.J.; Lee, C.C.; Lee, Y.C.; Wu, Y.S.; Hsu, T.A.; Yueh, A.; Chao, Y.S.; Chern, J.H.* “Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors”Bioorg. Med. Chem. Lett., 2009, 19, 4134-4138. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  22. Kang, I.J.; Wang, L.W.; Lee, C.C.; Lee, Y.C.; Chao, Y.S.; Hsu, T.A.; Chern, J.H.* “Design, synthesis, and anti-HCV activity of thiourea compounds” Bioorg. Med. Chem. Lett. 2009, 19, 1950-1955. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  23. Lee, Y.Z.; Yang, C.W.; Kang, I.J.; Wu, S.H.; Chao, Y.S.; Chern, J.H.; Lee, S.J. “Analogues of 2-phenyl-ethensulfonic acid phenyl ester have dual fuctions of inhibiting expression of inducible nitric oxide synthase and activating peroxisome proliferator-activated receptor ” Bioorg. Med. Chem. Lett. 2008, 18, 5676-5679. (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  24. Chen, T.C.; Liu, S.C.; Huang, P.N.; Chang, H.Y.; Chern, J.H.*; Shih, S.R.* “Antiviral activities of pyridyl imidazolidinone derivatives against enterovirus 71” J. Biomed. Sci. 2008, 15(3), 291-300. (*corresponding author) (IF=2.935; 45/124 (36%) /Medicine, Research & Experimental)
  25. Chern, J.H.*; Chang, C.S.; Tai, C.L.; Lee, Y.C.; Lee, C.C.; Kang, I.J.; Lin, Y.T.; Lee, C.Y.; Shih, S.R. “Synthesis and Antipicornavirus Activity of (R)- and (S)- 1-[5-(4′-Chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one” Bioorg. Med. Chem. Lett. 2005, 15(19), 4206-4211. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  26. Chang, C.S.; Lin, Y.T.; Shih, S.R.; Lee, C.C.; Lee, Y.C.; Tai, C.L.; Tseng, S.N.; Chern, J.H.* “Design, Synthesis, and Antipicornavirus Activity of 1-[5-(4-Arylphenoxy)alkyl]-3-pyridin-4-yl-imidazolidin-2-one Derivatives” J. Med. Chem., 2005, 48, 3522-3535. (*corresponding author) (IF=5.589; 3/59 (5 %) /Chemistry, Medicinal)
  27. Chern, J.H.*; Chen, C.C.; Shih, S.R. “DBPR-103: A Novel Anti-EV 71 Compound” SCBA/BioPharm 2004, 10 (3), 9-13. (*corresponding author)
  28. Chern, J.H.*; Lee, C.C.; Chang, C.S.; Lee, Y.C.; Tai, C.L.; Lin, Y.T.; Shia, K.S.; Lee, C.Y.; Shih, S.R. “Synthesis and Antienteroviral Activity of a Series of Novel, Oxime Ether-Containing Pyridyl Imidazolidinones” Bioorg. Med. Chem. Lett. 2004, 14 (20), 5051-5056. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  29. Shih, S.R.; Tsai, M.C.; Tseng, S.N.; Won, K.F.; Shia, K.S.; Li, W.T.; Chern, J.H.; Chen, G.W.; Lee, C.C.; Lee, Y.C.; Peng, K.C.; Chao, Y.S. “Mutation in Enterovirus 71 VP1 Capsid Protein Can Confer Resistance to the Inhibitory Effects of Pyridyl Imidazolidinone” Antimicrob. Agents Chemother. 2004, 48 (9), 3523-3529. (IF=4.415; 22/123 (18%) /Microbiology)
  30. Chern, J.H.*; Shia, K.S.; Hsu, T.A.; Tai, C.L.; Lee, C.C.; Lee, Y.C.; Chang, C.S.; Tseng, S.N.; Shih, S.R. “Design, Synthesis, and Structure-Activity Relationship of Pyrazolo[3,4-d]pyrimidines: A Novel Class of Potent Enterovirus Inhibitors ” Bioorg. Med. Chem. Lett. 2004, 14 (10), 2519-2525. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  31. Chern, J.H.*; Shia, K.S.; Chang, C.M.; Lee, C.C.; Lee, Y.C.; Tai, C.L.; Lin, Y.T.; Chang, C.S.; Tseng, H.Y. “Synthesis and In Vitro Cytotoxicity of 5-Substituted 2-Cyanoimino-4-imidazodinone and 2-Cyanoimino-4-pyrimidinone Derivatives” Bioorg. Med. Chem. Lett. 2004, 14 (5), 1169-1172. (*corresponding author) (IF=2.486; 23/59 (39 %) /Chemistry, Organic)
  32. Shia, K.S.; Li, W.T.; Chang, C.M.; Hsu, M.C.; Chern, J.H.; Leong, M.K.; Tseng, S.N.; Lee, C.C.; Lee, Y.C.; Chen, S.J.; Peng, K.C.; Tseng, H.Y.; Chang, Y.L.; Tai, C.L.; Shih, S.R. “Design, Synthesis, and Structure-Activity Relationship of Imidazolidinone Derivatives: A Novel Class of Potent and Selective Human Enterovirus 71 Inhibitors” J. Med. Chem., 2002, 45, 1644-1655. (IF=5.589; 3/59 (5 %) /Chemistry, Medicinal)
  33. Chow, T.J.; Hon, Y.S.; Jen, C.C.; Chern, J.H.; Lin, K.J. “Chemistry of Cage-Shaped Hydrocarbons. Ring Transformations on a Tricyclo[5.2.1.04,10] decane System” J. Chem.Soc., Perkin Trans 1., 1999, 1847.
  34. Chow, T.J.; Hon, Y.S.; Jen, C.C.; Liu, S.S.; Chern, J.H.; Lin, K.J. “Chemistry of Cage-Shaped Hydrocarbons. Reaction of Pentacyclo-[6.6.0.02,6.03,13.010,14]-tetradecane-4,11-diene” J. Chem.Soc., Perkin Trans 1., 1998, 1095.
  35. Chern, J.H.; Wu, H.J.; Wang, S.L.; Liao, F.L. “Synthesis of Carbon-Chain Tethered Bistetraoxa-Cage Compounds” J. Chinese Chem. Soc., 1998, 45, 139. (IF=0.879; 124/163 (76%) /Chemistry, Multidisciplinary)
  36. Wu, H.J.; Chern, J.H. “Chemical Transformation of Tetraacetal Tetraoxa-Cages to Aza-Cages and Amido-Cages Mediated by Iodotrimethylsilane and the Combination of Chlorotrimethylsilane and Sodium iodide in Acetonitrile” Tetrahedron 1998, 54, 5967. (IF=2.645; 22/59 (37%) /Chemistry, Organic)
  37. Wu, H.J.; Chern, J.H. “Chemical Transformation of 4,6-Dimethyl-2b-hydroxy-8-oxo-3,5,7-trioxatetracyclo-[7.2.1.04,11.06,10]dodecane ” J. Chinese Chem. Soc., 1997, 44, 71. (IF=0.879; 124/163 (76%) /Chemistry, Multidisciplinary)
  38. Lin, R.L.; Wu, C.Y.; Chern, J.H.; Wu, H.J. “Synthesis of Tetraacetal Tetraoxa-Cage Compounds with Alkyl Substituents at Different Sites of the Oxa-Cage Skeleton” J. Chinese Chem. Soc., 1996, 43, 289. (IF=0.879; 124/163 (76%) /Chemistry, Multidisciplinary)
  39. Wu, H.J.; Chern, J.H. “A Novel Hydride Rearrangement of Acetal Group of Tetraacetal Tetraoxa-Cages Mediated by Lewis Acid” J. Chem. Soc., Chem. Commun., 1997, 547. (IF=6.567; 21/163 (13%) /Chemistry, Multidisciplinary)
  40. Wu, H.J.; Chern, J.H. “A Novel One-Pot Conversion of Tetraoxa-Cages to Aza-Cages Mediated by Iodotrimethylsilane in Acetonitrile” Tetrahedron Lett. 1997, 38, 2887-2890. (IF=2.347; 25/59 (42%) /Chemistry, Organic)
  41. Wu, H.J.; Chern, J.H. “Synthesis of 4-Oxo- and 4-anti-Formyl-8,10,12,13-tetraoxapentacyclo-[5.5.1.03,11.05,9.08,12]tridecanes” Tetrahedron 1997, 53, 17653. (IF=2.645; 22/59 (37%) /Chemistry, Organic)
  42. Wu, H.J.; Chern, J.H.; Wu, C.Y. “Ozonolysis of 2-endo-7-anti-Diacylnorbornenes. A New Entry for the Synthesis of 2,4,6,13-Tetraoxapentacyclo-[5.5.1.03,11.05,9.08,12]tridecanes” Tetrahedron 1997, 53, 2401. (IF=2.645; 22/59 (37%) /Chemistry, Organic)
  43. Wu, H.J.; Tsai, S.H.; Chern, J.H.; Lin, H.C. “Synthesis of Diacetal Trioxa-Cage Compounds via a Sequential Cyclization Reaction of Norbornene Derivatives Induced by Electrophiles” J. Org. Chem. 1997, 62, 6367. (IF=4.785; 7/59 (12%) /Chemistry, Organic)
  44. Wu, H.J.; Chern, J.H. “A Remarkable Effect of C-O-C Bond Angle Strain on the Regioselective Double Nucleophilic Substitution of the Acetal Group of Tetraacetal Tetraoxa-Cages and a Novel Hydride Rearrangement of Tetraoxa-Cages” J. Org. Chem. 1997, 62, 3208. (IF=4.785; 7/59 (12%) /Chemistry, Organic)

PATENT APPLICATIONS (Anti-cancer Program)

  1. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” US patent pending, 2022 (US 17/829,917).
  2. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” ROC patent pending, 2022 (TW 111121451).
  3. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” AU patent pending, 2022 (AU 2022203580).
  4. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” JP patent pending, 2022 (JP 2022- 093400).
  5. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” CN patent pending, 2022 (NA).
  6. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” CA patent pending, 2022 (CA 3,161,246).
  7. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” KR patent pending, 2022 (KR 10-2022-0069995).
  8. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” SG patent pending, 2022 (SG 10202250120T).
  9. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” IN patent pending, 2022 (IN 202224033109).
  10. Chern J.H.; Yen W.C.; Yeh T.K.; Chen C.T.; Huang K.F.; Wang A.H. “Methods of Increasing Cell Phagocytosis” EP patent pending, 2022 (EP 22184666.0).

PATENT APPLICATIONS (Alzheimer’s Disease Program)

  1. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” EP patent pending, 2022 (EP 19855757.1).
  2. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” IN patent pending, 2022 (IN 202147006743).
  3. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” SG patent pending, 2022 (SG 11202101274X).
  4. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” CN patent granted, 2022 (CN 201980055577.3).
  5. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” CA patent granted, 2022 (CA 3,109,623).
  6. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” KR patent granted, 2022 (KR 10-2405760).
  7. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” JP patent granted, 2022 (特許第7035275號).
  8. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” AU patent granted, 2021 (AU2019333295).
  9. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” ROC patent granted, 2021 (TWI715156).
  10. Chern J.H.; Chen C.T.; Shih C.; Huang K.F.; Wang A.H. “Benzimidazole  Compounds and Use Thereof for Treating Alzheimer’s Disease or Huntington’s Disease” US patent granted, 2020 (US10,584,120B2).
  11. Chern J.H., Shie F.S., Chao Y.S. “Treatment of Neurodegenerative Disorders with Thiourea Compounds” ROC patent granted, 2014 (I450716).
  12. Chern J.H., Shie F.S., Chao Y.S. “Treatment of Neurodegenerative Disorders with Thiourea Compounds” US patent granted, 2012 (US 8,198,284 B2).

PATENT APPLICATIONS (Anti-HCV Program)

  1. Chern J.H. and Chao Y.S. “Proline Derivatives” EP patent granted, 2019 (EP2507232).
  2. 陳志豪，趙宇生 “脯氨酸衍生物” 澳門專利, 2016 (J/001913).
  3. 陳志豪，趙宇生 “脯氨酸衍生物” 香港專利, 2016 (HK1171439)
  4. Chern J.H. and Chao Y.S. “Proline Derivatives” AU patent granted, 2015 (AU2010325980).
  5. Chern J.H. and Chao Y.S. “Proline Derivatives” JP patent granted, 2015 (JP5753185).
  6. 陈志豪，赵宇生 “脯氨酸衍生物” 中國專利, 2015 (ZL 201080002506.6).
  7. 陳志豪，趙宇生 “脯氨酸衍生物” 中華民國專利, 2014 (I 429645).
  8. Chern J.H. and Chao Y.S. “Proline Derivatives” US patent granted, 2013 (US 8,415,482 B2).
  9. 陳志豪，徐祖安 康祐竣，王麗雯 李忠吉，李彥俊，吳彥顯，徐聖如 岳嶽 趙宇生“咪唑啉酮及咪唑啉硫酮衍生物” 中華民國專利, 2012 (I 361808).
  10. 陳志豪，徐祖安，康祐竣，王麗雯，李忠吉，李彥俊，趙宇生 “C型肝炎病毒抑制劑” 中華民國專利, 2012 (I 359137).
  11. Chern J.H., Hsu T.A., Kang I.J., Wang L.W., Lee C.C., Lee Y.C., Wu Y.S., Hsu S.J., Yueh A., Chao Y.S. “Imidazolidinone and Imidazolidinethione Derivatives” US patent granted, 2011 (US 7,939,523 B2).
  12. Chern J.H., Hsu, T.A., Kang I.J., Wang L.W., Lee C.C., Lee Y.C., Chao Y.S. “Thiourea Derivatives” US patent granted, 2011 (US 7,897,764 B2).
  13. Chern J.H., Hsu, T.A., Kang I.J., Wang L.W., Lee C.C., Lee Y.C., Chao Y.S. “Hepatitis C Virus Inhibitors” US patent granted, 2011 (US 7,985,763 B2).

PATENT APPLICATIONS (Anti-EV71 Program)

  1. Chern J.H., Lee C.C., Chang, C.S., Lee Y.C., and Shih S.R. “咪唑啉酮化合物” 中華民國專利, 2010 (發明第 324594 號).
  2. Chern J.H., Lee C.C., Chang, C.S., Lee Y.C., and Shih S.R. “Imidazolidinoe Compounds” US Patent granted, 2009 (US 7,501,445 B2).
  3. Chern J.H., Lee C.C., Chang, C.S., Lee Y.C., and Shih S.R. “Imidazolidinoe Compounds” US Patent granted, 2007 (US 7,259,174 B2).
  4. Chern J.H., Chang C.S., Lee C.C., Lee Y.C., Tai C.L., Chen C.T., Shih S.R.  “咪唑啉酮化合物” 中華民國專利, 2007 (發明第 281919 號).
  5. Chern J.H., Chang C.S., Lee C.C., Lee Y.C., Tai C.L., Chen C.T., Shih S.R. “Imidazolidinone Compounds” US Patent granted, 2006 (US 7,129,359 B2).
  6. Chern J.H., Shia K.S., Shih S.R., Hsu T.A., Tai C.L. “抗腸病毒化合物” 中華民國專利, 2006 (發明第 259083 號).
  7. Shia K.S., Li W.T., Chang C.M., Hsu M.C., Chern J.H., Shih S.R. “咪唑啉酮化合物” 中華民國專利, 2004 (發明第 203254 號).
  8. Chern J.H., Shia K.S., Shih S.R., Hsu T.A., Tai C.L.  “Anti-enterovirus Compounds” US Patent granted, 2003 (US 6,815,444 B2).
  9. Shia K.S., Li W.T., Chang C.M., Hsu M.C., Chern J.H., Shih S.R. “Imidazolidinone Compounds” US Patent granted, 2002 (US 6,706,739 B2).

Comments are closed.